This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Abacavir, Dolutegravir and Lamivudine is a combination regimen consisting of antiviral medications, which was approved for its medical use on 22nd August 2014

Mechanism of Action of undefined

Abacavir, Dolutegravir and Lamivudine Tablet is a combination of integrase strand transfer inhibitors and nucleoside analog reverse transcriptase inhibitors. It works by increasing the number of CD4 T cells and stimulates the immune system to fight against infections. Abacavir and Lamivudine inhibit the reverse transcriptase enzyme of the HIV-1, induce chain termination, and prevents the incorporation of viral DNA. Thereby, it reduces the viral load of HIV in the blood and decreases the severity of HIV infection.

Uses of undefined

Abacavir, Dolutegravir, and Lamivudine have been developed to treat Human Immunodeficiency Virus (HIV-1). Abacavir, Dolutegravir, and Lamivudine Tablet is indicated as a complete regimen for treating adults and children infected with HIV 1.

undefined Drug administaration and Dosage available

Abacavir, Dolutegravir and Lamivudine is available as film-coated tablets and oral suspension. The tablets consist of 600mg of Abacavir, 50mg of Dolutegravir, and 300mg of Lamivudine. The usual recommended dosage of this combination regimen is one tablet every day with or without food.

Warnings, Precautions and Side Effects of undefined


Do not take this medication if you have experienced hypersensitivity reactions to Abacavir, Dolutegravir or Lamivudine. During the Abacavir, Dolutegravir and Lamivudine Tablet treatment, your doctor will test you for hepatitis B virus and may periodically monitor your blood counts, bone mineral density, liver and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with diabetes, hypertension, high blood cholesterol, pancreatitis, bone disease, fractures, liver or kidney problems. Tell your healthcare provider if you have been tested for a gene variation called HLA-B*5701.


Adults of childbearing potential should consider using an effective contraceptive to prevent unwanted pregnancy. If you are pregnant or think you might be pregnant, your physician might suggest an alternative treatment as this combination regimen is not recommended during early pregnancy. Breastfeeding is not recommended due to potential transmission of HIV from mother to the baby.

Side Effects

The common side effects that are likely to occur while you are on the treatment with Abacavir, Dolutegravir, and Lamivudine Tablet are insomnia, tiredness and headache. Some serious adverse reactions include bone loss, worsening of Hepatitis B, kidney injury, immune reconstitution syndrome, lactic acidosis, and liver problems. If you experience any allergic reactions after taking this tablet, report to your doctor immediately.

Word Of Advice

Abacavir, Dolutegravir and Lamivudine can make you feel tired. Hence, you should avoid driving or handling machines during this treatment. 

Frequently Asked Question


1. KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.

2. GlaxoSmithKline., U.S. Food and Drug Administration, [Revised on Mar 2022] [Accessed on 19th Sep 2022],

3. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants, Clinical Pharmacology in Drug Development, 2021,10(9), 985–993,


The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.